Month: April 2025

– Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B) evaluating elraglusib have been selected for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, in Chicago, Illinois. Details...

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2024 for both the Group and the parent company. The numbers are in line with preliminary accounts released on 26  February 2025. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsHAVI20245967007LIEEXZXFJ8876-2024-12-31-no

ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets. Executive Vice President of R&D, Henriette Mersebach (MD), says: “We are very pleased with the European health authorities’ approval which allows us to provide this important treatment option to children and adolescents whose lives are impaired by uncontrolled tree pollen-induced respiratory allergy. Today’s approval marks another significant milestone...

SHEFFIELD, United Kingdom, April 23, 2025 (GLOBE NEWSWIRE) — Caro Holdings announces the release of its new AI Chat Agent platform – an intelligent, always-on assistant team built to help businesses save time, cut costs, and deliver top-tier customer service without hiring additional staff. Caro’s smart agents handle tasks that typically consume team resources, including:Instant Support – answering FAQs like return policies or product details Appointment Scheduling – enabling bookings through chat Order Tracking – real-time delivery updates Lead Qualification – asking smart questions to identify buyers Feedback Collection – gathering reviews and insightsDesigned to improve conversion rates and streamline onboarding, the platform enhances customer care with intelligent automation. “In a world...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, April 23, 2025 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced, upsized equity offering for aggregate gross proceeds of $20 million (the “Offering”). The net proceeds from the Offering will be used to advance and complete the development and pre-clinical testing of its Novasight 3.0 technology, with the goal of submitting a 510(k) clearance application to the U.S. Food and Drug Administration in Q3 of 2025. The Company also intends to use the net...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisor James “Jim” Verdi, CFP®, has joined LPL Financial’s broker-dealer, Registered Investment Advisor (RIA) and custodial platforms. He reported serving approximately $350 million in advisory, brokerage and retirement plan assets* and joins LPL from Osaic. Based in Smithtown, N.Y., Verdi founded Synergy Wealth Strategies in 2008, driven by the mission that investors deserve a reputable, stable and safe place to house their investments. The firm’s name comes from the definition of synergy: the combined power of a group of things when they are working together that is greater than the total power achieved by each working separately. Together with his team, Verdi takes a comprehensive and holistic approach to wealth management to help...